Nanotechnology Now - Press Release: Results To Date Of Keystone Nano’s Ceramide Nanoliposome Clinical Testing

Home > Press > Results To Date Of Keystone Nano’s Ceramide Nanoliposome Clinical Testing

Abstract:
Keystone Nano, Inc. announces that clinical testing of Ceramide NanoLiposome (CNL) has cleared many hurdles and is at an important phase of discovery. CNL has been extremely well tolerated in patients at increasing dose levels and is well tolerated in the first four dose levels tested. Testing at dose level five began April 30, 2018. The total number of escalations included in the trial is six.

Results To Date Of Keystone Nano’s Ceramide Nanoliposome Clinical Testing

State College, PA | Posted on May 7th, 2018

KN has also established, for this patient set, the drug half-life which is long and supports effective accumulation in tumors. Several patients have shown stable disease conditions while on the trial which is very encouraging, especially as these patients have not responded to standard treatments. Some patients who have stayed on the trial have been treated with many doses (32, 30, 22) of the drug without significant side effects.

The final dose escalations will be complete soon, and an additional twelve patients will be treated at the highest safe dose to further explore the anti-cancer effect of CNL. The company is planning to follow this study by treating more patients including Liver Cancer patients and monitoring the effectiveness of the new anti-cancer drug.
Ceramide is a biologically active lipid that is being examined as a potential treatment for liver cancer, as well as in breast cancer, leukemia and pancreatic cancer. Ceramide NanoLiposome seeks to kill cancer cells while leaving normal cells alone, providing treatment without undue toxicity. Keystone Nano has Intellectual Property and protections for this potential therapy.

Liver Cancer kills approximately 27,000 people in the United States and 700,000 worldwide each year. There is currently no effective therapy for this disease. Keystone Nano was recently awarded orphan drug status for the treatment of liver cancer with ceramides in the United States.

The trial is partially funded by the National Institutes of Health National Cancer Institute. KN is working closely with the University of Maryland Greenebaum Cancer Institute, the Medical University of South Carolina and the University of Virginia where patients are being treated.

####

About Keystone Nano, Inc.
Based in State College, Pennsylvania KN is working at the interface between nanotechnology and medicine. In addition to developing Ceramide NanoLiposome, the company is working on additional products using NanoJackets for RNA delivery and for Photo-Immuno Nanotherapy. NanoJackets are calcium phosphate nanoparticles with many unique features. For more information visit www.keystonenano.com.

For more information, please click here

Contacts:
Jeff Sirianni
Managing Member
Monarch Solutions, LLC
Mobile: (703) 728.6837
www.Monarchsls.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: